Literature DB >> 10891979

Multiple sclerosis-from probable to definite diagnosis: a 7-year prospective study.

A Achiron1, Y Barak.   

Abstract

OBJECTIVES: To investigate the rate of progression from probable to clinically definite multiple sclerosis (MS) and to define patients who had rapidly (within 1 year) progressed to a definite diagnosis.
DESIGN: A 7-year prospective study. PATIENTS: A group of 163 patients experiencing their first episode of neurologic symptoms suggestive of MS. All patients had brain magnetic resonance imaging that demonstrated at least 3 demyelinating lesions at onset.
RESULTS: Within the follow-up period (mean, 42 months; range, 13-84 months), 136 patients (83.4%) had an additional relapse and were thus defined as having clinically definite MS, whereas 27 patients (16.6%) were defined as having clinically probable MS. Most of the 136 patients with clinically definite MS (57.6%, 94 patients) experienced the additional relapse within 1 year. Demographic and clinical parameters at presentation were analyzed to identify variables predictive of rapid progression (within 1 year) to clinical definite MS. Motor involvement at onset was the only clinical parameter associated with rapid progression to a definite diagnosis. Survival curves demonstrated that polysymptomatic involvement and higher Extended Disability Status Scale score at presentation correlated with rapid progression to definite diagnosis.
CONCLUSION: Most patients with a diagnosis of probable MS and positive brain magnetic resonance imaging will progress rapidly to clinically definite MS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10891979     DOI: 10.1001/archneur.57.7.974

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  16 in total

1.  Ocular motor measures of cognitive dysfunction in multiple sclerosis II: working memory.

Authors:  Meaghan Clough; Laura Mitchell; Lynette Millist; Nathaniel Lizak; Shin Beh; Teresa C Frohman; Elliot M Frohman; Owen B White; Joanne Fielding
Journal:  J Neurol       Date:  2015-04-09       Impact factor: 4.849

2.  Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF.

Authors:  Jens Kuhle; Raija L P Lindberg; Axel Regeniter; Matthias Mehling; Francine Hoffmann; Markus Reindl; Thomas Berger; Ernst W Radue; David Leppert; Ludwig Kappos
Journal:  J Neurol       Date:  2007-02       Impact factor: 4.849

3.  Cognitive impairment in probable multiple sclerosis.

Authors:  A Achiron; Y Barak
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-04       Impact factor: 10.154

4.  Updates on clinically isolated syndrome and diagnostic criteria for multiple sclerosis.

Authors:  Jacqueline F Marcus; Emmanuelle L Waubant
Journal:  Neurohospitalist       Date:  2013-04

5.  Relation between EDSS and monosymptomatic or polysymptomatic onset in clinical manifestations of multiple sclerosis in Babol, northern Iran.

Authors:  Seyed Mohammad Masood Hojjati; Seyyed Ali Hojjati; Mobina Baes; Ali Bijani
Journal:  Caspian J Intern Med       Date:  2014

Review 6.  Multiple sclerosis.

Authors:  David A Hafler
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

7.  Predicting the course of relapsing-remitting MS using longitudinal disability curves.

Authors:  Anat Achiron
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

8.  Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis.

Authors:  M S Freedman; C Metzig; L Kappos; C H Polman; G Edan; H-P Hartung; D H Miller; X Montalban; J Yarden; L Spector; E Fire; N Dotan; S Schwenke; V Lanius; R Sandbrink; C Pohl
Journal:  Mult Scler       Date:  2011-12-19       Impact factor: 6.312

Review 9.  Demyelinating disorders: update on transverse myelitis.

Authors:  Chitra Krishnan; Adam I Kaplin; Carlos A Pardo; Douglas A Kerr; Sanjay C Keswani
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 6.030

10.  Clinical predictors of early second event in patients with clinically isolated syndrome.

Authors:  Ellen M Mowry; Mila Pesic; Barbara Grimes; Serina R Deen; Peter Bacchetti; Emmanuelle Waubant
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.